MDWD MediWound Ltd.

3.09
+0.04  (+1%)
Previous Close 3.05
Open 3.04
Price To Book 4.61
Market Cap 83,982,613
Shares 27,178,839
Volume 41,010
Short Ratio
Av. Daily Volume 68,538
Stock charts supplied by TradingView

NewsSee all news

  1. MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States

    YAVNE, Israel, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management,

  2. BARDA Initiates the Procurement of NexoBrid for Emergency Response

    YAVNE, Israel and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ:VCEL) today announced that the U.S. Biomedical Advanced

  3. MediWound Continues NexoBrid's Global Expansion Through a New Distribution Agreement in Australia, New Zealand and Singapore with Balance Medical

    YAVNE, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management,

  4. MediWound Initiates U.S. Phase 2 Adaptive Design Study of EscharEx® for Treatment of Venous Leg Ulcers

    YAVNE, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (the "Company") (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound

  5. MediWound Reports Third Quarter 2019 Financial Results

    Total revenues of $5.1 million, driven primarily by revenues from development services Initiated U.S. NexoBrid expanded access treatment (NEXT) protocol, with plans on track for NexoBrid® BLA filing in the second

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to be initiated 4Q 2019.
EscharEx
Chronic and other hard-to-heal wounds
BLA filing due 2Q 2020.
NexoBrid
Severe burns
Phase 2 trial initiation announced December 3, 2019 with interim assessment due by end of 2020.
EscharEx
Venous leg ulcers (VLU’s)

Latest News

  1. MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States

    YAVNE, Israel, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management,

  2. BARDA Initiates the Procurement of NexoBrid for Emergency Response

    YAVNE, Israel and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ:VCEL) today announced that the U.S. Biomedical Advanced

  3. MediWound Continues NexoBrid's Global Expansion Through a New Distribution Agreement in Australia, New Zealand and Singapore with Balance Medical

    YAVNE, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management,

  4. MediWound Initiates U.S. Phase 2 Adaptive Design Study of EscharEx® for Treatment of Venous Leg Ulcers

    YAVNE, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (the "Company") (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound

  5. MediWound Reports Third Quarter 2019 Financial Results

    Total revenues of $5.1 million, driven primarily by revenues from development services Initiated U.S. NexoBrid expanded access treatment (NEXT) protocol, with plans on track for NexoBrid® BLA filing in the second

  6. MediWound to Report Third Quarter 2019 Financial Results and Host a Conference Call and Webcast on November 14

    YAVNE, Israel, Nov. 06, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management,

  7. Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol

    CAMBRIDGE, Mass. and YAVNE, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL) and MediWound Ltd. (NASDAQ:MDWD) today announced initiation of the NexoBrid® expanded access treatment protocol

  8. NexoBrid® Highlighted in 39 Presentations at the 18th European Burns Association Congress in Helsinki

    YAVNE, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound care